The clinical significance of establishing these new entities is highlighted by distinct differences in median survival: 10 months for patients with MDS with biallelic TP53 inactivation, and 15 months for those with bone marrow fibrosis, compared to 45 months for the entire study cohort. This evidence concerns the gene TP53 and myelodysplastic syndrome.